Phase I Trial of BAY1251152 for Advanced Blood Cancers

Inclusion Criteria: * Male or female patients aged ≥18 years * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and Life expectancy of at least 12 weeks * Patients are able and willing to provide bone marrow biopsies/aspirates as requested by the protocol * Patients with confirmed advanced hematological malignancies * Negative serum pregnancy test * Women and men of reproductive potential must agree to use highly effective contraception when sexually active. * Ability to understand and the willingness to sign a written informed consent. * Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤1.5 times ULN) * Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: * Presence of active/uncontrolled central nervous system involvement * History of clinically significant cardiac disease; uncontrolled hypertension * Left ventricular ejection fraction (LVEF) \< 45% * Allogeneic stem cell transplant within 100 days before first dose of study drug * Known history of human immunodeficiency virus (HIV) infection * Chronic or active hepatitis B or C, requiring antiviral therapy * Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study * Serious, uncontrolled infection * Unresolved chronic toxicity \> grade 1 from prior therapy * Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study